Helus Pharma's HLP004 showed strong anxiety relief in a Phase 2 trial, but its stock dropped 20.5% on March 5, 2026.

Helus Pharma reported positive top-line results from a Phase 2 study of HLP004, showing a 10.4-point mean reduction in anxiety symptoms on the HAM-A scale at six weeks for patients on the 20 mg dose, with 67% response and 39% remission rates at six months. The company plans to publish data on its related compound HLP003 for major depressive disorder in late 2026. Despite the results, the company's stock fell 20.52% to $6.78 in pre-market trading on March 5, 2026.